In young children 2 to less than 6 years old with obesity due to BBS
IMCIVREE helped reduce weight measures over 1 year
Actor portrayals
IMCIVREE helped young children aged 2 to less than 6 years achieve early and clinically meaningful reduction in weight measures
IMCIVREE was studied in two first-ever Phase 3 clinical trials that included children and adults with obesity due to BBS. In the year-long study of children aged 2 to less than 6 years old, 5 young children were included. All children in the clinical trial had to have a certain body mass index (BMI) and weight in the 97th percentile or higher.
Young children taking IMCIVREE saw an ~10% average reduction in BMI after 1 year.
Young children achieved early and clinically meaningful reduction in weight measures
- Young children saw an early meaningful reduction in weight measures*
- Young children continued to see a reduction in weight measures by BMI Z-score over the course of their first year of treatment
A BMI Z-score was used to measure the reduction in BMI in children. BMI Z-scores are reliable measures of weight in children who are still growing because they take into account height, age, and gender.
*A clinically meaningful reduction is generally defined as a reduction of greater than or equal to 0.2 in BMI Z-score.
No change to diet or exercise:
In the clinical trial, people were not required to change their diet or exercise routine.
IMCIVREE reduced the severity of obesity in young children living with BBS
You may be more familiar with viewing a child's growth on a chart that compares how their height and weight match up with other children the same age. This is called a growth chart. The growth chart here shows a representation of a 4-year-old girl with obesity due to BBS. It demonstrates how IMCIVREE might help to lower her BMI after 1 year of treatment, based on results from the IMCIVREE clinical study.
Representative growth chart for a child with obesity due to BBS before and after IMCIVREE
After 1 year on IMCIVREE, she would see a 15 percentage-point reduction in BMI as a percentage of the 95th percentile, dropping into the obesity (class 1) category.
Without IMCIVREE, her BMI may have continued to go up, leading to severe obesity (class 3) by age 7 and remaining in this category as she ages.
Not an actual patient. Growth chart is based on females 2 to 20 years of age and is for illustrative purposes only.
Treating children with IMCIVREE early may help reduce the severity of weight gain as they get older.
Resources and support tailored to your child’s journey
As a caregiver, you may need clear information to help you prepare for doctor visits or support in understanding your child's condition. Your Rhythm lnTune Patient Education Manager (PEM)† is here with personalized educational resources.
†Patient Education Managers are employees of Rhythm Pharmaceuticals and do not provide medical care or advice. We encourage you to always speak to your healthcare providers regarding your medical care.
Use our Doctor Discussion Guide to start the conversation about treatment with IMCIVREE.
Learn about the possible side effects
of IMCIVREE.